amprenavir

(redirected from 141W94)
Also found in: Dictionary, Wikipedia.

amprenavir

 [am-pren´ah-vir]
an HIV protease inhibitor used in the treatment of human immunodeficiency virus (HIV) infection; administered orally.

amprenavir

/am·pren·a·vir/ (am-pren´ah-vir) an HIV protease inhibitor used in the treatment of HIV-1 infection.

amprenavir

an antiviral (protease inhibitor).
indication It is used to treat HIV in combination with other antiretroviral agents.
contraindication Known hypersensitivity prohibits its use.
adverse effects Life-threatening side effects include Stevens-Johnson syndrome and acute hemolytic anemia. Other serious adverse effects include new-onset diabetes, hyperglycemia, and exacerbation of preexisting diabetes mellitus. Common side effects include diarrhea, abdominal pain, nausea, paresthesia, and rash.

amprenavir

A protease inhibitor used with other antiretrovirals for managing HIV-1 (e.g., nelfinavir, indinavir or saquinavir).

Adverse effects
Nausea, vomiting, diarrhoea, headache, perioral paraesthesias, gastric discomfort, rash, hyperglycaemia, diabetes, acute haemolytic anaemia, spontaneous bleeding in haemophiliacs, fat redistribution.

amprenavir

AIDS A protease inhibitor in clinical trials for treating HIV, used in combination with other protease inhibitors–eg, nelfinavir, indinavir, or saquinavir Adverse effects N&V, diarrhea, headache, perioral paresthesias, stomach discomfort, rash; other effects include hyperglycemia, DM, acute hemolytic anemia, spontaneous bleeding in hemophiliacs, and fat redistribution. See AIDS, Combination therapy, HIV, Protease inhibitor.

amprenavir

A protease inhibitor drug used to treat HIV infections. A brand name is Agenerase.
References in periodicals archive ?
In the context of current therapy, the Phase II triple combination study shows that 141W94 displayed potent antiviral activity at all three doses tested in combination with AZT and 3TC," commented Mike Rogers, Ph.
Stephane de Wit of Saint-Pierre University Hospital in Brussels, Belgium, reported results from the "Vanguard" study, a pilot efficacy trial of three doses (900 mg, 1050 mg and 1200 mg, twice daily) of 141W94 in combination with Retrovir(R) (AZT) and Epivir(R) (3TC).
Three pivotal Phase III clinical trials are ongoing to assess the tolerability and antiviral activity of 141W94 in combination therapy in HIV-positive adults and children.
There is significant momentum in the 141W94 clinical
response of 141W94 when added to the NRTI therapy the patient is
conducting a series of ongoing Phase II studies with 141W94 in
The evaluation of 141W94 with nucleoside reverse transcriptase inhibitors (NRTI) in children will enhance the positioning of the compound in the combination HIV market," stated Dr.
Glaxo Wellcome's double-blind, pivotal Phase III clinical trial is designed to evaluate the tolerability, antiviral efficacy, and durability of the antiviral response of 141W94 compared to placebo, when added to the NRTI
These two pediatric studies, coupled with the ongoing Phase II and pivotal Phase III trial in adults, are part of a broad series of clinical studies underway or planned by Glaxo Wellcome to evaluate the use of 141W94 in HIV-infected patients.
These data suggest that the antiviral activity of 141W94 (VX-478) increases with increasingly larger doses.
Treatment with 141W94 (VX-478) was generally well-tolerated at the doses tested with the most commonly reported adverse events including diarrhea/loose stools, rash and headache.
We look forward to the results of additional Glaxo Wellcome studies designed to test 141W94 (VX-478) in combination with other antiviral agents in adult and pediatric patients.